Rise Valuation Multiples

Discover Rise's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Pilulka Lekarny, Farmacosmo, Wellgistics Health, SC Ropharma and more.

Rise Overview

About Rise

Rise Inc is engaged in real estate business. The operations of the company include development of real estate and rental of real estate. The company conduct business to develop hotels, condominiums, residential properties, and commercial facilities.


Founded

1947

HQ

Japan

Employees

3

Sectors

Financials (LTM)

Revenue: $3M
Net Income: $315K

EV

$13M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Rise Financials

Rise reported last 12-month revenue of $3M.

In the same LTM period, Rise generated $315K in net income.

Revenue (LTM)


Rise P&L

In the most recent fiscal year, Rise reported revenue of $3M and EBITDA of $881K.

Rise is profitable as of last fiscal year, with gross margin of 86%, EBITDA margin of 32%, and net margin of 12%.

See analyst estimates for Rise
LTMLast FY202320242025202620272028
Revenue$3M$3M$2M$2M$3M
Gross Profit-$2M$2M$2M$2M
Gross Margin-86%84%84%85%
EBITDA-$881K$544K$609K$826K
EBITDA Margin-32%25%26%31%
EBIT Margin11%11%3%8%10%
Net Profit$315K$317K($14K)$25K$252K
Net Margin12%12%(1%)1%9%

Financial data powered by Morningstar, Inc.

Rise Stock Performance

Rise has current market cap of $16M, and enterprise value of $13M.

Market Cap Evolution


Rise's stock price is $0.16.

Rise share price decreased by 3.9% in the last 30 days, and by 31.6% in the last year.

See more trading valuation data for Rise
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$13M$16M-0.1%-3.9%9.4%-31.6%$0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Rise Valuation Multiples

Rise trades at 4.7x EV/Revenue multiple, and 14.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Rise

EV / Revenue (LTM)


Rise Financial Valuation Multiples

As of August 7, 2026, Rise has market cap of $16M and EV of $13M.

Rise has a P/E ratio of 50.3x.

LTMLast FY202320242025202620272028
EV/Revenue4.7x4.7x5.9x5.5x4.9x
EV/EBITDA-14.7x23.8x21.3x15.7x
EV/EBIT43.7x43.4x170.0x68.0x46.4x
EV/Gross Profit-5.5x7.1x6.5x5.7x
P/E50.3x49.9xn/mn/m62.8x
EV/FCF-37.8x(166.6x)55.1x37.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Rise Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Rise Margins & Growth Rates

In the most recent fiscal year, Rise reported gross margin of 86%, EBITDA margin of 32%, and net margin of 12%.

See estimated margins and future growth rates for Rise

Rise Margins

Last FY202420252026202720282029
Gross Margin86%84%85%86%
EBITDA Margin32%26%31%32%
EBIT Margin11%8%10%11%
Net Margin12%1%9%12%
FCF Margin13%10%13%13%

Rise Growth Rates

23/2424/2525/2626/2727/2828/29
Revenue Growth8%12%3%
Gross Profit Growth9%14%3%
EBITDA Growth12%36%7%
EBIT Growth150%47%7%
Net Profit Growth(278%)894%26%
FCF Growth(402%)47%(1%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Rise Operational KPIs

Rise's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.7M for the same period.

Rise's Rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Rise's Rule of X is 39% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Rise
Last FY202320242025202620272028
Rule of 4035%---
Bessemer Rule of X39%---
Revenue per Employee$0.9M---
Opex per Employee$0.7M---
Opex to Revenue75%80%76%75%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Rise Competitors

Rise competitors include Pilulka Lekarny, Farmacosmo, Wellgistics Health, SC Ropharma, BlueMTec, PetMeds, Talea Group, d1000, MARX Biotech and Fangzhou.

Most Rise public comparables operate across Pharmacies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Pilulka Lekarny0.4x-25.8x-
Farmacosmo0.5x-71.2x-
Wellgistics Health----
SC Ropharma0.2x-4.5x-
BlueMTec0.4x-64.9x-
PetMeds0.1x0.1x(1.0x)(0.8x)
Talea Group0.6x-24.4x-
d10000.3x-4.0x-

This data is available for Pro users. Sign up to see all Rise competitors and their valuation data.

Start Free Trial

Acquisitions by Rise

Rise has acquired 1 company to date.

Last acquisition by Rise was on March 1st 2026. Rise acquired Passmed for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Rise

Passmed
Description
Passmed is a Japanese provider of education and training for pharmacists and students. Operations include new drug information distribution and matching services.
HQ CountryJapan
HQ City
Amagasaki
Deal Date1 Mar 2026
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Rise acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Rise

When was Rise founded?Rise was founded in 1947.
Where is Rise headquartered?Rise is headquartered in Japan.
How many employees does Rise have?As of today, Rise has over 3 employees.
Is Rise publicly listed?Yes, Rise is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of Rise?Rise trades under 8836 ticker.
When did Rise go public?Rise went public in 1972.
Who are competitors of Rise?Rise main competitors include Pilulka Lekarny, Farmacosmo, Wellgistics Health, SC Ropharma, BlueMTec, PetMeds, Talea Group, d1000, MARX Biotech, Fangzhou.
What is the current market cap of Rise?Rise's current market cap is $16M.
What is the current revenue of Rise?Rise's last 12 months revenue is $3M.
What is the current EV/Revenue multiple of Rise?Current revenue multiple of Rise is 4.7x.
What is the current net income of Rise?Rise's last 12 months net income is $315K.
How many companies Rise has acquired to date?As of August 2026, Rise has acquired 1 company.
What was the largest acquisition by Rise?None of the M&A deals Rise has completed have disclosed valuations.
What companies Rise acquired?Rise acquired Passmed.
In how many companies Rise has invested to date?Rise hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Rise

Lists including Rise

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial